Matthew Majewski

Vice President

Mr. Matthew Majewski has a track record of providing life science clients with analytically based solutions to their strategic issues.

He has led a wide range of corporate and asset-specific strategy engagements, many of which have focused on pricing and market access. Mr. Majewski has deep experience in the specialty disease space and has provided insights to many clients with rare disease, oncology, and cell & gene therapy assets across the retail, specialty, and hospital channels. Prior to joining CRA, Mr. Majewski was a consultant at a biopharmaceutical organization where he developed and managed market strategies for pre-launch products and designed and managed market organizations.

Selected engagements

  • 01
    Establishing real-world testing and treatment patterns for EGFR NSCLC patients
    Oncology-focused biotech was looking to establish real-world testing and treatment patterns among EGFR NSCLC patients in US, EU, Japan, and Greater China...
    View engagement
  • 02
    Modeling the financial implications of innovative gene therapy business models
    Biotech client was looking to evaluate the financial implications of various innovative business models/strategic offerings for its novel gene therapy.
    View engagement
  • 03
    Creating a pricing and contracting strategy for a novel bispecific antibody within the oncology therapeutic area
    A leading pharmaceutical company sought support in developing a launch pricing and access strategy for their new bispecific antibody (BsAb) oncology asset...
    View engagement

Credentials